Navigation Links
ECNP expresses concern at AstraZeneca neuroscience pull-out
Date:2/6/2012

The European College of Neuropsychopharmacology expresses its deep concern at the recently announced withdrawal by AstraZeneca from neuroscience drug research. AstraZeneca's pull-out is especially disturbing given that it follows a series of similar withdrawals in the last two years by major pharmaceutical companies. There is a growing sense that neuroscience in Europe is now facing a severe crisis.

"Disorders of the brain are Europe's pre-eminent health care concern of the future," says ECNP president, Joseph Zohar, professor of psychiatry at Tel Aviv University. "Medications, properly targeted, are in almost all cases the key to effective treatment. To have a major player like AstraZeneca, with an outstanding history of innovation and development in disorders of the brain, pull out of the field in this way will inevitably affect Europeans' access to high-quality medications in the future. This is not good news for patients."

Research sponsored by ECNP shows that more than a third of all Europeans experience some form of mental disorder in any given year, at a total cost to the region of some 800 billion per annum. The direct medical costs of these disorders constitute almost a quarter of the European Union's total health care expenditure, with indirect costs from work absences to enforced early retirement almost twice as much again. The social and emotional costs are incalculable.

AstraZeneca's pull-out is especially disturbing given that it follows a series of similar withdrawals in the last two years by major pharmaceutical companies, including GlaxoSmithKline, Pfizer, Merck, Sanofi and Novartis, who have all significantly downsized their neuroscience commitment. There is a growing sense that neuroscience in Europe is now facing a severe crisis.

"Neuroscience has long been one of Europe's outstanding scientific strengths," says ECNP secretary, Sven Ove gren, professor of neuroscience at Sweden's Karolinska Institutet. "The loss of hundreds of research positions in the field is an enormous blow. Coming on top of similar closures at almost all of Europe's big pharma companies, it's a very worrying development. What's now urgently needed is united action from all those interested in Europe's neuroscientific future to ensure that the region's neuroscience research base of which pharma is an indispensible part does not suffer permanent and possibly irreversible damage."


'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
43-140-55734
European College of Neuropsychopharmacology
Source:Eurekalert

Related medicine news :

1. Supportive of intent of ACO proposed rule, ACP expresses concern
2. IHRSA Expresses Its Ardent Support of America's First-Ever National Physical Activity Plan and Accepts Role as Co-Chair of Implementation Sub-Committee
3. U.S. African Chamber of Commerce President Expresses Concern over Health Care Bill
4. Cases of Tamiflu-Resistant Flu Concern Experts
5. Women should still be concerned about hormone replacement therapy, say McMaster researchers
6. Buildup of Newer Flame Retardants Concerns Scientists
7. Potential concern about drugs in clinical trial
8. Group sex among adolescents a public health concern, new study says
9. 15 new conservation concerns
10. Concerns about teen sexting overblown, according to new UNH research
11. Internists address dual concerns of privacy and protection of health data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The ... for Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch ... 8. , Project Entrepreneur’s second annual venture competition ignites bold ideas by providing ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis ... A type of groin injury, it occurs when the muscles around the pelvis ... in and around the lower torso, as well as accompanying tenderness and weakness. ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare ... will hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will ... chain and value analysis professionals have a ‘seat at the table’ with clinical ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... announce the launch of a months-long rebranding effort. This includes the introduction of ... focus group discussions and market research, we learned that a simple, proactive approach ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading provider ... its latest products to the Deaf Seniors of America Conference, April 4-7 at the ... meet with knowledgeable ASL friendly staff from Harris Communications and to try out the ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)...  iCAD (Nasdaq: ICAD), an industry-leading provider of ... for the early identification and treatment of cancer, ... Approval (PMA) from the U.S. Food and Drug ... concurrent-read computer aided detection solution for digital breast ... on the PowerLook® Breast Health Solutions platform.  ...
(Date:3/27/2017)... , March 27, 2017  Twist Bioscience, a ... synthesis, today announced that it raised an additional $33 ... of $166 million. "It is an ... expand our reach and continue to deliver industry-leading gene ... market segments," commented Emily M. Leproust, Ph.D., CEO of ...
(Date:3/27/2017)... 2017 Cota Healthcare, the leading ... medicine, today announced the signing of a ... to help improve clinical and cost outcomes ... part of this agreement, which expands significantly ... January 2016, teams from across Novartis Pharmaceuticals ...
Breaking Medicine Technology: